Skip to main content

Lifevantage Corp

For the period ended Jun 30, 2026. Filed Aug 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Aug 27, 2026

LFVN$4.56-13.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

The following documents are being filed as part of this report:

Financial Statements

(a)(1) Financial Statements. The following consolidated financial statements of LifeVantage Corporation and Report of Independent Registered Public Accounting Firm are included in a separate section of this Annual Report on Form 10-K.

(a)(2) All schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions or are inapplicable, or because the required information is included in the financial statements or notes thereto, and therefore have been omitted.

Exhibits

(a)(3) The following exhibits are filed as part of, or incorporated by reference into, the Annual Report on Form 10-K.

ExhibitNo.Document DescriptionFiled Herewith or Incorporated by Reference From
3.1Certificate of IncorporationExhibit 3.1 to Form 8-K filed with the SEC on March 13, 2018.
3.2Amended and Restated BylawsExhibit 3.1 to Form 8-K filed with the SEC on August 15, 2019.
3.3Certificate of Designation of Series A Junior Participating Preferred Stock of the CompanyExhibit 3.1 to Form 8-K filed with the SEC on August 31, 2023.
3.4Certificate of Elimination of Series A Junior Participating Preferred Stock of Registrant, filed November 18, 2024Exhibit 3.1 to Form 8-K filed with the SEC on November 19, 2024.
4.1Form of Common Stock CertificateExhibit 4.1 to Form 8-K filed with the SEC on March 13, 2018.
4.3Rights Agreement, dated as of August 30, 2023, by and between the Company and Computershare Trust Company, N.A., as Rights AgentExhibit 4.1 to Form 8-K filed with the SEC on August 31, 2023
10.1Cooperation Agreement, dated February 14, 2024, by and among the Company, the entities and persons listed on Exhibit A thereto, and the entities and persons listed on Exhibit B theretoExhibit 10.1 to Form 8-K filed with the SEC on February 15, 2024.
10.2.1#LifeVantage Corporation 2017 Long-Term Incentive Plan, as amendedAnnex A to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024.
10.2.2#LifeVantage Corporation 2019 Employee Stock Purchase Plan, as amendedAnnex B to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024.
ExhibitNo.Document DescriptionFiled Herewith or Incorporated by Reference From
10.2.3#Evolve Compensation Plan (United States), as amended on November 1, 2024Exhibit 10.3 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.4#Evolve Compensation Plan (Australia), as amended on November 1, 2024Exhibit 10.4 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.5#Evolve Compensation Plan (New Zealand), as amended on November 1, 2024Exhibit 10.5 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.6#Evolve Compensation Plan (Japan), as amended on November 1, 2024Exhibit 10.6 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.7#Evolve Compensation Plan (Canada), as amended on November 1, 2024Exhibit 10.7 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.8#Evolve Compensation Plan (Mexico), as amended on November 1, 2024Exhibit 10.8 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.9#Evolve Compensation Plan (UK), as amended on November 1, 2024Exhibit 10.9 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.10#Evolve Compensation Plan (EU), as amended on November 1, 2024Exhibit 10.10 to Form 10-Q filed for the fiscal quarter ended December 31, 2024 filed with the SEC on February 5, 2025.
10.2.11#Evolve Compensation Plan (Taiwan)Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025.
10.2.12#Evolve Compensation Plan (Hong Kong)Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025.
10.2.13#Evolve Compensation Plan (Singapore)Exhibit 10.11 to Form 10-Q filed for the fiscal quarter ended March 31, 2025 filed with the SEC on May 6, 2025.
10.3#Form of Restricted Stock Grant Agreement for the 2017 Long-Term Incentive PlanExhibit 99.2 to the Registration Statement on Form S-8 filed with the SEC on March 27, 2017.
10.4#Form of Stock Unit Agreement for the 2017 Long-Term Incentive PlanExhibit 99.3 to the Registration Statement on Form S-8 filed with the SEC on March 27, 2017.
10.5#LifeVantage Corporation 2019 Employee Stock Purchase Plan, as amendedAnnex B to the Registrant’s Proxy Statement on Schedule 14A, filed with the SEC on September 20, 2024.
10.6Form of Indemnification AgreementExhibit to 99.1 to Form 8-K filed with the SEC on March 13, 2018.
ExhibitNo.Document DescriptionFiled Herewith or Incorporated by Reference From
10.7#Form of Key Executive Benefits AgreementExhibit 10.09# to Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on August 28, 2024.
10.8Loan Agreement, dated April 12, 2024, by and between the Company and Bank of America, N.A.Exhibit 10.1 to Form 8-K filed with the SEC on April 16, 2024.
10.9Continuing and Unconditional Guaranty, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.Exhibit 10.2 to Form 8-K filed with the SEC on April 16, 2024.
10.10Security and Pledge Agreement, dated April 12, 2024, by and among the Company, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.Exhibit 10.3 to Form 8-K filed with the SEC on April 16, 2024.
10.11Amendment No. 1 to Loan Agreement, dated September 22, 2025, by and between the Company and Bank of America, N.AFiled herewith.
10.12Lease Agreement, dated November 14, 2019, by and between Traverse Ridge Center III and the CompanyExhibit 10.1 to Form 10-Q filed for the fiscal quarter ended December 31, 2019 with the SEC on January 28, 2020.
10.13Lease Agreement, dated May 26, 2023, by and between Sumitomo Mitsui Trust Bank, Limited and LifeVantage Japan in US/English FormatExhibit 10.1 to Form 10-Q filed for the fiscal quarter ended September 30, 2023 filed with the SEC on November 9, 2023.
10.14*Commercial Supply Agreement, dated January 31, 2014, by and between the Company and Deseret Laboratories, Inc.Exhibit 10.1 to Form 10-Q for the fiscal quarter ended March 31, 2014 filed with the SEC on May 6, 2014.
10.15*Service Agreement, dated June 1, 2014, by and between IntegraCore, LLC and the CompanyExhibit 10.29 to Form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 10, 2014.
10.16*Commercial Supply Agreement, dated May 30, 2014, by and between the Company and Wasatch Product DevelopmentExhibit 10.30 to Form 10-K for the fiscal year ended June 30, 2014 filed with the SEC on September 10, 2014.
10.17#**Key Executive Benefits Agreement, dated April 15, 2026, by and between the Company and Terrence MooreheadFiled herewith.
10.18#Independent Contractor Consultant Agreement, dated April 15, 2026, by and between the Company and Michael BeindorffExhibit 10.1 to Form 8-K filed with the SEC on April 16, 2026
10.19#Transition Agreement and General Release, dated April 15, 2026, by and between the Company and Steven FifeExhibit 10.2 to Form 8-K filed with the SEC on April 16, 2026
ExhibitNo.Document DescriptionFiled Herewith or Incorporated by Reference From
19.1Insider Trading Policy, amended and restated on October 30, 2025Filed herewith.
21.1List of SubsidiariesFiled herewith.
23.1Consent of Deloitte & Touche, LLPFiled herewith.
24.1Power of AttorneySignature page to this report.
31.1Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith.
31.2Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.Filed herewith.
32.1***Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith.
32.2***Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Furnished herewith.
97.1Company Policy for the Recovery of Erroneously Awarded Compensation (Clawback Policy)Exhibit 97.1 to Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC on August 28, 2024.
101The following financial information from the registrant’s Annual Report on Form 10-K for the year ended June 30, 2026 formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Other Comprehensive Income; (iii) Consolidated Statement of Stockholders’ Deficit; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements, tagged as blocks of text.Filed herewith.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)Filed herewith.
#Management contract or compensatory plan.
*The company has been granted confidential treatment for portions of this agreement. Accordingly, certain portions of this agreement have been omitted in the version filed with this report and such confidential portions have been filed with the SEC.
**Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions are both not material and are the type of information that the Registrant treats as private or confidential.
***This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. 1350, and is not being filed for purposes of Section 18 of the Exchange Act and is not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.